Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Innovent Biologics, Inc.
Innovent Biologics develops and sells innovative medicines for cancer, cardiovascular, metabolic, autoimmune and eye diseases.
Innovent Biologics is a Chinese drugmaker that invents and sells medicines for some of the world's most serious diseases — cancer, heart and metabolic conditions, autoimmune disorders, and eye diseases. Its job is to take a molecule from a lab idea all the way to a pharmacy shelf, then get doctors to prescribe it and patients to use it.
The company's best-known product is sintilimab, sold as Tyvyt, a cancer immunotherapy that helps the body's immune system attack tumors. It was developed with Eli Lilly and is one of the first homegrown Chinese drugs of its kind to win approval and reach patients at scale. Innovent also sells a growing lineup of other medicines, including treatments for eye disease and metabolic conditions, some of which it licenses from partners such as Sanofi and some it develops itself. The money comes from selling these drugs, mainly in China, to hospitals and patients through the country's public and private insurance systems. What makes the business interesting is the flywheel: a successful drug throws off cash that funds clinical trials for the next wave of candidates, so Innovent is essentially a pipeline company that keeps seeding new bets. Its biggest vulnerability is that China's public insurance system pushes drug prices down hard, and global rivals like Merck and Roche compete in the same disease areas.
Innovent has been pushing overseas too, striking licensing deals that let bigger Western companies develop its molecules in the US and Europe in exchange for upfront cash and future royalties. That gives it a second income stream without having to build a global sales force itself. The bet is that Chinese biotech can now invent drugs the whole world wants, not just copy them.
Saved answer · last researched 12 Nov 2026